Is Recursion Pharma a buy because of Nvidia’s endorsement? Indeed, Nvidia’s bet on Recursion is notable, but despite the stake and collaboration, the name isn’t without its fair share of risks.

The Motley Fool has a disclosure policy. Why Recursion Pharmaceuticals Stock Tanked on Tuesday Person in a lab gazing into a microscope.© Getty Images ...

Recursion's AI-designed cancer drugs REC-3565 and REC-617 show early clinical promise, with one patient responding unexpectedly well to treatment.

The Verdict Recursion Pharmaceuticals offers a compelling investment for exposure to AI-driven drug discovery, backed by a strong balance sheet.

After layoffs at Recursion, the company’s CEO writes about taking inspiration from an unexpected source: “The Art of Racing in the Rain.” ...

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading higher and trending. The company on Tuesday announced a reduction in personnel and infrastructure aimed at extending its cash runway.

Recursion Pharmaceuticals is laying off a fifth of its workforce in connect with a previously announced streamlining of the AI biotech’s pipeline.

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) are tumbling on Tuesday. The move comes as the S&P 500 and Nasdaq Composite both slipped by 0.6%. The data from an April survey revealed Tuesday ...

Recursion’s pipeline shuffle follows the company’s acquisition of AI development peer Exscientia late last year.

Recursion Pharmaceuticals stock isn't a good fit for risk-averse investors. The company remains unprofitable and is losing more money as it ramps up clinical development of several candidates.

Volume & Open Interest Development In today's trading context, the average open interest for options of Recursion Pharmaceuticals stands at 3202.67, with a total volume reaching 6,136.00. The ...